NYSEAMERICAN:CLDI Calidi Biotherapeutics (CLDI) Stock Price, News & Analysis → “Crash Insurance” For Your Retirement (From Unstoppable Prosperity) (Ad) Free CLDI Stock Alerts $0.22 0.00 (-0.75%) (As of 03:29 PM ET) Add Compare Share Share Today's Range$0.21▼$0.2350-Day Range N/A52-Week Range$0.14▼$13.79Volume183,275 shsAverage Volume750,098 shsMarket Capitalization$8.00 millionP/E RatioN/ADividend YieldN/APrice Target$3.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort Interest Get Calidi Biotherapeutics alerts: Email Address Calidi Biotherapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,377.3% Upside$3.25 Price TargetShort InterestHealthy4.02% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.09 out of 5 stars 3.5 Analyst's Opinion Consensus RatingCalidi Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCalidi Biotherapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Calidi Biotherapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.02% of the outstanding shares of Calidi Biotherapeutics have been sold short.Short Interest Ratio / Days to CoverCalidi Biotherapeutics has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Calidi Biotherapeutics has recently increased by 859.73%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCalidi Biotherapeutics does not currently pay a dividend.Dividend GrowthCalidi Biotherapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CLDI. Previous Next 0.6 News and Social Media Coverage Search Interest5 people have searched for CLDI on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Calidi Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders16.70% of the stock of Calidi Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 12.53% of the stock of Calidi Biotherapeutics is held by institutions.Read more about Calidi Biotherapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsCould this Tiny Biotech End Disease Forever?Imagine a revolutionary treatment capable of editing out ANY disease. By literally "cutting" the genetic instructions that cause illness, and "pasting" in corrected DNA to restore perfect health.Access my full "Cut & Paste" profit analysis now. About Calidi Biotherapeutics Stock (NYSEAMERICAN:CLDI)Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.Read More CLDI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CLDI Stock News HeadlinesMay 1, 2024 | businesswire.comCalidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual MeetingApril 23, 2024 | finance.yahoo.comJoin Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24May 8, 2024 | Crypto 101 Media (Ad)Tech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. April 23, 2024 | businesswire.comJoin Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on April 24April 19, 2024 | businesswire.comCalidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public OfferingApril 16, 2024 | msn.comWhy Calidi Biotherapeutics (CLDI) Shares Are Down Over 50%April 16, 2024 | investorplace.comWhy Is Calidi Biotherapeutics (CLDI) Stock Down 51% Today?April 16, 2024 | businesswire.comCalidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public OfferingMay 8, 2024 | Crypto 101 Media (Ad)Tech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. April 9, 2024 | finance.yahoo.comCalidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company’s Novel Immunotherapies at the AACR Annual Meeting 2024April 9, 2024 | businesswire.comCalidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company's Novel Immunotherapies at the AACR Annual Meeting 2024March 16, 2024 | investorplace.comCLDI Stock Earnings: Calidi Biotherapeutics Misses EPS for Q4 2023March 15, 2024 | businesswire.comCalidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial ResultsMarch 11, 2024 | businesswire.comCalidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian CancerFebruary 12, 2024 | finance.yahoo.comCalidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming ConferenceFebruary 8, 2024 | msn.comCalidi Biotherapeutics Shares Informal Financial UpdateFebruary 2, 2024 | msn.comCalidi Biotherapeutics Conducts Private Equity SaleJanuary 9, 2024 | uk.finance.yahoo.comCalidi Biotherapeutics, Inc. (CLDI)January 8, 2024 | finance.yahoo.comCalidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory BoardDecember 12, 2023 | finance.yahoo.comCalidi Biotherapeutics Announces Appointment of Pharmaceutical Industry Veteran David LaPré to its Board of DirectorsDecember 5, 2023 | finance.yahoo.comCalidi Biotherapeutics To Present New Preclinical Data Highlighting Cell-based Virotherapy (SuperNova) Platform Technology at SITC 2023December 5, 2023 | finance.yahoo.comCalidi Biotherapeutics Announces Appointment of Andrew Jackson as Chief Financial OfficerDecember 5, 2023 | finance.yahoo.comCalidi Biotherapeutics Announces Key Leadership Promotions and New Board AppointmentDecember 5, 2023 | finance.yahoo.comCalidi Biotherapeutics (NYSEAM: CLDI) Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023)December 5, 2023 | finance.yahoo.comCalidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial ResultsDecember 5, 2023 | finance.yahoo.comCalidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform and Updates Anticipated Clinical MilestonesSee More Headlines Receive CLDI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Calidi Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNYSEAMERICAN:CLDI CUSIPN/A CIKN/A Webcalidibio.com Phone858-794-9600FaxN/AEmployees41Year FoundedN/APrice Target and Rating Average Stock Price Target$3.25 High Stock Price Target$4.50 Low Stock Price Target$2.00 Potential Upside/Downside+1,377.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,220,000.00 Net MarginsN/A Pretax Margin-75,660.00% Return on EquityN/A Return on Assets-100.93% Debt Debt-to-Equity RatioN/A Current Ratio0.42 Quick Ratio0.42 Sales & Book Value Annual Sales$50,000.00 Price / Sales156.38 Cash FlowN/A Price / Cash FlowN/A Book Value($0.23) per share Price / Book-0.96Miscellaneous Outstanding Shares35,540,000Free Float29,603,000Market Cap$7.82 million OptionableNot Optionable Beta0.57 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Allan J. Camaisa (Age 63)CEO & Chairman of the Board Comp: $306.18kMs. Wendy Pizarro Campbell Esq. (Age 52)Chief Administrative Officer, Chief Legal Officer, Chief Diversity Officer & Corporate Secretary Comp: $295.4kDr. Boris Minev M.D. (Age 60)Ph.D., President of Medical & Scientific Affairs and Interim Chief Medical Officer Comp: $400.1kMr. Andrew C. Jackson (Age 55)Chief Financial Officer Dr. Amish Patel Ph.D. (Age 47)Senior Vice President of Technical Operations Mr. Stephen Thesing (Age 58)Chief Business Officer More ExecutivesKey CompetitorsPalisade BioNASDAQ:PALITitan PharmaceuticalsNASDAQ:TTNPCreative Medical TechnologyNASDAQ:CELZSorrento TherapeuticsNASDAQ:SRNEFresh Tracks TherapeuticsNASDAQ:FRTXView All CompetitorsInstitutional OwnershipSpectrum Asset Management Inc. NB CA Bought 166,494 shares on 4/23/2024Ownership: 0.468%View All Institutional Transactions CLDI Stock Analysis - Frequently Asked Questions Should I buy or sell Calidi Biotherapeutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Calidi Biotherapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CLDI shares. View CLDI analyst ratings or view top-rated stocks. What is Calidi Biotherapeutics' stock price target for 2024? 2 analysts have issued 12 month price targets for Calidi Biotherapeutics' stock. Their CLDI share price targets range from $2.00 to $4.50. On average, they predict the company's stock price to reach $3.25 in the next year. This suggests a possible upside of 1,377.3% from the stock's current price. View analysts price targets for CLDI or view top-rated stocks among Wall Street analysts. Are investors shorting Calidi Biotherapeutics? Calidi Biotherapeutics saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 1,430,000 shares, an increase of 859.7% from the March 31st total of 149,000 shares. Based on an average daily trading volume, of 632,000 shares, the short-interest ratio is presently 2.3 days. View Calidi Biotherapeutics' Short Interest. Who are Calidi Biotherapeutics' major shareholders? Calidi Biotherapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Spectrum Asset Management Inc. NB CA (0.47%). How do I buy shares of Calidi Biotherapeutics? Shares of CLDI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:CLDI) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyAI “wealth window” is closing June 25thParadigm PressElon Musk Secret Crypto Plot ExposedCrypto 101 MediaThe AI Stock that’s Disrupting Every IndustryStockEarningsShocking: One AI startup's revenue could surge 4,735%Manward PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calidi Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
